{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:46:49Z","timestamp":1785037609164,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,8]]},"DOI":"10.1038\/s41416-025-03289-7","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T18:55:15Z","timestamp":1764442515000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-3962","authenticated-orcid":false,"given":"Jiarui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7796-1557","authenticated-orcid":false,"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-4180","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-7024","authenticated-orcid":false,"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3768","authenticated-orcid":false,"given":"Changsong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"3289_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21:354\u201369.","journal-title":"Nat Rev Clin Oncol"},{"key":"3289_CR2","doi-asserted-by":"crossref","unstructured":"Li J, Liu C, Zhang P, Shen L, Qi C. Optimizing CAR T cell therapy for solid tumours: a clinical perspective. Nat Rev Clin Oncol. 2025;22:953\u201368.","DOI":"10.1038\/s41571-025-01075-1"},{"key":"3289_CR3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Med. 2022;28:1189\u201398.","journal-title":"Nature Med"},{"key":"3289_CR4","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nature Med. 2024;30:2224\u201334.","journal-title":"Nature Med"},{"key":"3289_CR5","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, et al. Claudin-18 isoform 2-specific CART-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405:2049\u201360.","journal-title":"Lancet"},{"key":"3289_CR6","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline. J Clin Oncol. 2021;39:3978\u201392.","journal-title":"J Clin Oncol"},{"key":"3289_CR7","doi-asserted-by":"publisher","first-page":"e15234-e","DOI":"10.1200\/JCO.2020.38.15_suppl.e15234","volume":"38","author":"J Li","year":"2020","unstructured":"Li J, Yang K, Zhao L, Bai C, Sun Z. Impact of corticosteroids use on efficacy of immune checkpoint inhibitors in cancer patients: A meta-analysis. Journal Clin Oncol. 2020;38:e15234-e.","journal-title":"Journal Clin Oncol"},{"key":"3289_CR8","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137:3272\u20136.","journal-title":"Blood"},{"key":"3289_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert M-L, Mor U, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature Med. 2023;29:906\u201316.","journal-title":"Nature Med"},{"key":"3289_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28:713\u201323.","journal-title":"Nat Med"},{"key":"3289_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024;14:84.","journal-title":"Blood Cancer J"},{"key":"3289_CR12","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/cncr.35316","volume":"130","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang B, Zhang Q, Zhou H, Sun Q, Zhou Y, et al. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia. Cancer. 2024;130:2660\u20139.","journal-title":"Cancer"},{"key":"3289_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3289_CR14","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1093\/bioinformatics\/btw183","volume":"32","author":"JR Kultima","year":"2016","unstructured":"Kultima JR, Coelho LP, Forslund K, Huerta-Cepas J, Li SS, Driessen M, et al. MOCAT2: a metagenomic assembly, annotation and profiling framework. Bioinformatics. 2016;32:2520\u20133.","journal-title":"Bioinformatics"},{"key":"3289_CR15","first-page":"3","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal. 2011;17:3.","journal-title":"EMBnetjournal"},{"key":"3289_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-485","volume":"11","author":"MP Cox","year":"2010","unstructured":"Cox MP, Peterson DA, Biggs PJ. SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinforma. 2010;11:485.","journal-title":"BMC Bioinforma"},{"key":"3289_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1093\/bioinformatics\/btp336","volume":"25","author":"R Li","year":"2009","unstructured":"Li R, Yu C, Li Y, Lam TW, Yiu SM, Kristiansen K, et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics. 2009;25:1966\u20137.","journal-title":"Bioinformatics"},{"key":"3289_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nmeth.2066","volume":"9","author":"N Segata","year":"2012","unstructured":"Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. 2012;9:811\u20134.","journal-title":"Nat Methods"},{"key":"3289_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-161","volume":"10","author":"W Luo","year":"2009","unstructured":"Luo W, Friedman MS, Shedden K, Hankenson KD, Woolf PJ. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinform. 2009;10:161.","journal-title":"BMC Bioinform"},{"key":"3289_CR20","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.celrep.2014.04.041","volume":"7","author":"C Libert","year":"2014","unstructured":"Libert C, Dejager L. How steroids steer T cells. Cell Rep. 2014;7:938\u20139.","journal-title":"Cell Rep"},{"key":"3289_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Munoz J, De Guibert S, Vose JM, Bartlett NL, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194:690\u2013700.","journal-title":"Br J Haematol"},{"key":"3289_CR22","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377:2531\u201344.","journal-title":"New Engl J Med"},{"key":"3289_CR23","doi-asserted-by":"crossref","unstructured":"Wang X, Qi Y, Li H, Liu F, Cao J, Chen W, et al. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed\/refractory multiple myeloma treated with CAR-T therapy. Front. Immunol. 2022;13:943004.","DOI":"10.3389\/fimmu.2022.943004"},{"key":"3289_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943\u20137.","journal-title":"Oncologist"},{"key":"3289_CR25","first-page":"705","volume":"16","author":"S Si","year":"2020","unstructured":"Si S, Teachey DT. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;16:705\u201314.","journal-title":"Ther Clin Risk Manag"},{"key":"3289_CR26","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020;8:e001361.","journal-title":"J Immunother Cancer"},{"key":"3289_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137.","journal-title":"Science"},{"key":"3289_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1312","volume":"13","author":"Z Han","year":"2023","unstructured":"Han Z, Cheng S, Dai D, Kou Y, Zhang X, Li F, et al. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer. Clin Transl Med. 2023;13:e1312.","journal-title":"Clin Transl Med"},{"key":"3289_CR29","doi-asserted-by":"crossref","unstructured":"Wang X, Fang Y, Liang W, Wong CC, Qin H, Gao Y, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024;42:1729\u20131746.e8.","DOI":"10.1016\/j.ccell.2024.08.019"},{"key":"3289_CR30","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1158\/2326-6066.CIR-19-1014","volume":"8","author":"Z Peng","year":"2020","unstructured":"Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, et al. The gut microbiome is associated with clinical response to anti-PD-1\/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res. 2020;8:1251\u201361.","journal-title":"Cancer Immunol Res"},{"key":"3289_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101251","volume":"4","author":"CG Kim","year":"2023","unstructured":"Kim CG, Koh JY, Shin SJ, Shin JH, Hong M, Chung HC, et al. Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response. Cell Rep. Med. 2023;4:101251.","journal-title":"Cell Rep. Med"},{"key":"3289_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1158\/2326-6066.CIR-18-0174","volume":"6","author":"T Hamada","year":"2018","unstructured":"Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6:1327\u201336.","journal-title":"Cancer Immunol Res"},{"key":"3289_CR33","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, Perales MA, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11:e459\u2013e70.","journal-title":"Lancet Haematol"},{"key":"3289_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00741-2","volume":"12","author":"KC Miller","year":"2022","unstructured":"Miller KC, Johnson PC, Abramson JS, Soumerai JD, Yee AJ, Branagan AR, et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022;12:146.","journal-title":"Blood Cancer J"},{"key":"3289_CR35","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OA Clark","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198\u2013214.","journal-title":"J Clin Oncol"},{"key":"3289_CR36","doi-asserted-by":"publisher","first-page":"E399","DOI":"10.1002\/ajh.26313","volume":"96","author":"JN Barreto","year":"2021","unstructured":"Barreto JN, Bansal R, Hathcock MA, Doleski CJ, Hayne JR, Truong TA, et al. The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. Am J Hematol. 2021;96:E399\u2013E402.","journal-title":"Am J Hematol"},{"key":"3289_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Lievin","year":"2022","unstructured":"Lievin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transpl. 2022;57:431\u20139.","journal-title":"Bone Marrow Transpl"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03289-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03289-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:55:01Z","timestamp":1769615701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03289-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,8]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03289-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of Peking University Cancer Hospital (2018YJZ75). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent before participation in this trial","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}